Parathyroid hormone for osteoporosis treatment

Formosan Journal of Musculoskeletal Disorders

Volumn 2, Issue 4, 2011, Pages 113-117

  Lin, Wei Peng ^a   Lin, Jinn ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Fracture healing; Osteogenesis; Osteoporosis; Parathyroid hormone

Indexed keywords

ALENDRONIC ACID; CALCIUM; GLUCOCORTICOID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; VITAMIN D;

BONE DENSITY; BONE DEVELOPMENT; CHONDROGENESIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; HORMONAL THERAPY; HORMONE ACTION; HORMONE BINDING; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE;

EID: 82955232393     PISSN: 22107940     EISSN: 22107959     Source Type: Journal    
DOI: 10.1016/j.fjmd.2011.09.001     Document Type: Review

References (29)

1. Potts J.T. Parathyroid hormone: past and present. J Endocrinol 2005, 187:311-325.
2. Dempster D.W., Parisien M., Silverberg S.J., Liang X.G., Schnitzer M., Shen V., Shane E., et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999, 84:1562-1566.
3. Rubin M.R., Bilezikian J.P. New anabolic therapies in osteoporosis. Curr Opin Rheumatol 2002, 14:433-440.
4. Roschger P., Dempster D.W., Zhou H., Paschalis E.P., Silverberg S.J., Shane E., Bilezikian J.P., et al. New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. J Bone Miner Res 2007, 22:717-723.
5. Misof B.M., Roschger P., Cosman F., Kurland E.S., Tesch W., Messmer P., Dempster D.W., et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003, 88:1150-1156.
6. Roschger P., Paschalis E.P., Fratzl P., Klaushofer K. Bone mineralization density distribution in health and disease. Bone 2008, 42:456-466.
7. Kneissel M., Boyde A., Gasser J.A. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 2001, 28:237-250.
8. Stroup J., Kane M.P., Abu-Baker A.M. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 2008, 65:532-539.
9. Stroup J.S., Rivers S.M., Abu-Baker A.M., Kane M.P. Two year changes in bone mineral density and T scores in patients treated at a pharmacist-run Teriparatide clinic. Pharmacotherapy 2007, 27:779-788.
10. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
11. Marcus R., Wang O., Satterwhite J., Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:18-23.
12. Chen P., Miller P.D., Recker R., Resch H., Rana A., Pavo I., Sipos A.A. Increases in bone mineral density correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 2007, 22:1173-1180.
13. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
14. Body J.J., Gaich G.A., Scheele W.H., Kulkarni P.M., Miller P.D., Peretz A., Dore R.K., et al. A randomized double-blind trial to compare the efficacy of Teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:4528-4535.
15. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Rotter R.C., Jasqui S., et al. Differential effects of teriparatide and alendronate on markers of bone remodeling and areal and volumetric bone density in women with osteoporosis. J Bone Miner Res 2003, 18(Suppl 2):S40.
16. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., Dempster D., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
17. Ettinger B., San Martin J., Crans G., Pavo I. Differential effects of Teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
18. Boonen S., Marin F., Obermayer-Pietsch B., Simoes M.E., Barker C., Glass E.V., Hadji P., et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of Teriparatide treatment in 30. postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008, 93:852-860.
19. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., Kaufman J.M., et al. The effect of Teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
20. Kaufman J.M., Orwoll E., Goemaere S., San Martin J., Hossain A., Dalsky G.P., Lindsay R., et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510-516.
21. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
22. Saag K.G., Shane E., Boonen S., Marin F., Donley D.W., Taylor K.A., Dalsky G.P., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
23. Aspenberg P., Genant H.K., Johansson T., Nino A.J., See K., Krohn K., García-Hernández P.A., et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010, 25:404-414.
24. Resmini G., Iolascon G. 79-year-old post-menopausal woman with humerus fracture during teriparatide treatment. Aging Clin Exp Res 2007, 19(Suppl 4):30-31.
25. S.V. Bukata, L. Kaback, D.G. Reynolds, R.J. O'Keefe, R.N. Rosier. 1-34 PTH at physiologic doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: an observational cohort of 145 patients. Presented at the 55th Annual Meeting of the Orthopaedic Research Society. Las Vegas, NV; February 25, 2009.
26. P. Peichl, E. Krankenhaus Wien-Waehring, G. Holzer. Parathyroid hormone 1-84 accelerates fracture healing in pubic bones of elderly osteoporotic women (poster). Presented at The American Society for Bone and Mineral Research, 31st Annual Meeting, 2009. [accessed 09.10]. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx%3Faid%3D9d4e83f0-6302-4327-8a9d-758dc56cc703.
27. Kakar S., Einhorn T.A., Vora S., Miara L.J., Hon G., Wigner N.A., Toben D., et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 2007, 22:1903-1912.
28. O'Loughlin P.F., Cunningham M.E., Bukata S.V., Tomin E., Poynton A.R., Doty S.B., Sama A.A., et al. Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine 2009, 34:121-130.
29. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:95-96.